Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Stearic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.71 |
| ▸ | PPARG | P37231 | 7/20 | 0.71 |
| ▸ | PPARD | Q03181 | 7/20 | 0.71 |
| ▸ | PPARA | Q07869 | 7/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.71 |
| ▸ | TSHR | P16473 | 4/20 | 0.71 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.71 |
| ▸ | FABP4 | P15090 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | TLR2 | O60603 | 2/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.71 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.71 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.71 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | ESR1 | P03372 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Myristic Acid SCHEMBL28567039 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Palmitic Acid SCHEMBL9107897 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Nonanoate SCHEMBL30561579 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Nonanoate SCHEMBL30561576 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Decanoic Acid SCHEMBL5739296 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Behenic Acid SCHEMBL1857976 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Dodecanoate SCHEMBL23781813 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Octanoic Acid SCHEMBL31743253 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL10596204 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Nonanoate SCHEMBL30561573 | 1.00 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287627-A1 | Recyclable Composition for Paper Coating | BASF SE (DE) | 2023-09-14 | — | — | US | claimed |
| CN-115667627-A | Recyclable compositions for paper coatings | 巴斯夫欧洲公司 | 2023-01-31 | — | — | CN | claimed |
| US-20260054267-A1 | PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALE | ICEUTICA PTY LTD (AU) | 2026-02-26 | — | — | US | disclosed |
| US-20250235461-A1 | Formulation of Meloxicam | ICEUTICA PTY LTD (AU) | 2025-07-24 | — | — | US | disclosed |
| US-20250084043-A1 | FORMULATION OF METAXALONE | ICEUTICA INC. | 2025-03-13 | — | — | US | disclosed |
| US-20250049720-A1 | Method for improving the dissolution profile of a biologically active material | ICEUTICA PTY LTD. (AU) | 2025-02-13 | — | — | US | disclosed |
| US-20240390871-A1 | Production of encapsulated nanoparticles at high volume fractions | ICEUTICA PTY LTD. (AU) | 2024-11-28 | — | — | US | disclosed |
| US-20240150304-A1 | FORMULATION OF METAXALONE | ICEUTICA INC. | 2024-05-09 | — | — | US | disclosed |
| US-20230414630-A1 | Novel Formulation of Meloxicam | iCeutica, Inc. (AU) | 2023-12-28 | — | — | US | disclosed |
| US-20230398234-A1 | NOVEL FUNGAL COMPOIND FORMULATIONS AND THEIR THERAPEUTIC METHODS OF USE | MYDECINE INNOVATIONS GROUP INC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230356232-A1 | PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALE | ICEUTICA PTY LTD. (AU) | 2023-11-09 | — | — | US | disclosed |
| US-20230287627-A1 | Recyclable Composition for Paper Coating | BASF SE (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230133244-A1 | Method for the Production of Commercial Nanoparticle and Microparticle Powders | ICEUTICA PTY LTD. (AU) | 2023-05-04 | — | — | US | disclosed |
| US-20230128622-A1 | NOVEL FORMULATION OF MELOXICAM | ICEUTICA PTY LTD. (AU) | 2023-04-27 | — | — | US | disclosed |
| CN-115667627-A | Recyclable compositions for paper coatings | 巴斯夫欧洲公司 | 2023-01-31 | — | — | CN | disclosed |
| EP-4096442-A1 | SOLID ADSORBENT COMPOSITIONS FOR PURIFYING LIQUIDS | The Dallas Group of America, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20220235017-A1 | FORMULATION OF METAXALONE | ICEUTICA INC. | 2022-07-28 | — | — | US | disclosed |
| WO-2022094054-A1 | NOVEL FUNGAL COMPOUND FORMULATIONS AND THEIR THERAPEUTIC METHODS OF USE | MYDECINE INNOVATIONS GROUP INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| CN-110604721-B | Abiraterone acetate preparation | 太阳药业环球公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260054267-A1 | PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALE | FLNB, PRNP, CTSD | GPR84 4684/4885PPARG 3590/4885PPARD 2734/4885 |
| US-20230398234-A1 | NOVEL FUNGAL COMPOIND FORMULATIONS AND THEIR THERAPEUTIC METHODS OF USE | ERG28, DPM1, MAN2B1 | GPR84 4280/4885PPARG 4587/4885PPARD 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.